Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.

Psychiatry research - 30 Oct 2014

Tybura Piotr, Trześniowska-Drukała Beata, Bienkowski Przemyslaw, Beszlej Aleksander, Frydecka Dorota, Mierzejewski Pawel, Samochowiec Agnieszka, Grzywacz Anna, Samochowiec Jerzy

Abstract excerpt

The primary aim of the present study was to assess the possible associations between dopaminergic, serotonergic, and glutamatergic system-related genes and adverse events after antipsychotic treatment in paranoid schizophrenia patients. The second aim of the study was to compare the intensity of these symptoms between atypical (ziprasidone and olanzapine) and typical (perazine) antipsychotic drugs. One-hundred...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Basal Ganglia Diseases
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Monoamine Oxidase

Share to Olanzapine

Share to Overweight

Share to Receptor, Serotonin, 5-HT2A

Share to Receptors, Kainic Acid

Share to Schizophrenia, Paranoid

Source

Identifiers

PMID: 24930580
DOI: 10.1016/j.psychres.2014.05.039

Genes

COMT
DRD2
GRIK3
MAOA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.PMID 24930580Read ↗

Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.Semantic proximity Read ↗

Genetics of Common Antipsychotic-Induced Adverse EffectsSemantic proximity Read ↗

Pharmacogenetics of AntipsychoticsSemantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effects.Semantic proximity Read ↗

The pharmacogenetics of antipsychotic-induced adverse events.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced side effectsSemantic proximity Read ↗

Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical ImplicationsSemantic proximity Read ↗

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes.Semantic proximity Read ↗

[Pharmacogenetic-based risk assessment of antipsychotic-induced extrapyramidal symptoms].Semantic proximity Read ↗

Into a Deeper Understanding of CYP2D6's Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders.Semantic proximity Read ↗

Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.Semantic proximity Read ↗

New findings in pharmacogenetics of schizophreniaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.